The city’s leader Carrie Lam is formally withdrawing a controversial extradition bill which set off months of anti-government protests. Pete Sweeney and Robyn Mak talk about what this latest concession means, as well as the economic impact of the unres…
WeWork has reason to slash its IPO valuation, given the shared-office outfit’s lofty last funding round. But as Robert Cyran explains, the move would tarnish management’s credibility without addressing business model concerns, suggesting the company sh…
Pharma companies that contributed to America’s opioid crisis could end up paying $100 billion in settlements – but it may not be well spent. Robert Cyran eyes the mistakes made over tobacco payments in the 1990s, and suggests a better way to generate f…
Oil and gas companies are usually in the crosshairs on climate risk. But the water industry is a big greenhouse-gas emitter, and droughts and floods are a major source of corporate risk and opportunity, Antony Currie explains. Time for banks and invest…
Samsung heir Jay Y. Lee could be headed back to jail after South Korea’s Supreme Court ruled that a bribery case against him should be reviewed anew by a lower tribunal. Robyn Mak explains what it means for the world’s biggest smartphone maker.
Argentine President Mauricio Macri wants to restructure the country’s debt. If there’s an actual default, it would be the ninth in around 200 years. If Macri succeeds, though, there just might be a glimmer of hope for his probable successor.
Aug 28 – Peloton claims a high-tech mantle in its newly released IPO prospectus. And while the stationary bike company burns cash and has dual-class shares, Robert Cyran explains that its core business depends on retaining customer loyalty in an exerci…
Johnson & Johnson shares rose after a judge said it should pay $572 million for its part in Oklahoma’s opioid epidemic. Though the company is appealing, investors might be better off seeing the decision as a warning of more payouts to come, as Robert C…
Bristol-Myers Squibb has taken a step toward closing its deal for Celgene with the $13 bln sale of the latter’s psoriasis drug to Amgen. Richard Beales says the rich price lends credence to Bristol-Myers’ claim that Celgene was undervalued, and deservi…
Aug 23 – Twitter and Facebook have swept Beijing-controlled spam accounts from their systems. Twitter says it won’t take advertising from state-controlled media anymore. Pete Sweeney and Robyn Mak go through what it means, and how much it will cost U.S…